Answers are grounded in this paper and cite their sources.
How to best use tyrosine kinase inhibitors (TKIs) of BCR-ABL after allogeneic stem cell transplantation for Philadelphia chromosome–positive acute lymphoblastic leukemia (ALL) is unknown but will almost certainly not be addressed by a definitive randomized trial. Saini and colleagues provide a large body of observational data to reinforce earlier circumstantial evidence favoring prophylactic use of TKIs for at least 2 years posttransplant.
No takes yet. Share an insight, caveat, or question.
Saini et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: